NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEUTREXIN (trimetrexate glucuronate) is an injectable antimetabolite approved in 1993 for treating Pneumocystis jirovecii pneumonia (PCP), particularly in immunocompromised patients. It functions as a dihydrofolate reductase inhibitor that disrupts nucleotide synthesis in rapidly dividing cells. The drug is administered intravenously and requires concurrent leucovorin rescue to mitigate toxicity.
LOE Approaching
With LOE approaching and minimal current market presence (0 linked jobs), this product offers limited commercial growth opportunities and likely operates as a small, niche maintenance team focused on managed care and specialty pharmacy channels.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEUTREXIN offers minimal career growth as a legacy, niche product approaching loss of exclusivity with zero current job openings. Roles would focus on managed care defense and specialty channel support rather than innovation or team expansion. This is a maintenance assignment suitable only for professionals seeking stability in a defined, shrinking market.
Specialty Pharmacy Manager
Worked on NEUTREXIN at Immune-Onc Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.